Is Ingrezza (valbenazine) approved for treating tics?
Yes. Ingrezza (valbenazine) is used for adults with tardive dyskinesia (TD) and other dopamine-related movement disorders, but it is not a standard treatment for tic disorders such as Tourette syndrome or other chronic motor/vocal tics.
What does “for tics” usually mean—Tourette syndrome specifically?
Most people who ask about “Ingrezza for tics” are really asking about Tourette syndrome (TS) or other tic disorders. In those conditions, treatment typically focuses on behavioral therapy and medications such as alpha-2 agonists or antipsychotics, depending on age and severity. Ingrezza is not commonly used as a first-line tic medication.
Why are people mixing Ingrezza up with tic treatments?
Tics and tardive dyskinesia can look similar to non-specialists because both involve involuntary movements. But they come from different mechanisms and are treated differently, so a medication approved for TD does not automatically translate to a tic-disorder indication.
Are there any exceptions or off-label uses?
Off-label prescribing can happen, but indication approval is different from off-label practice. If you’re deciding whether it’s appropriate for a specific tic diagnosis, the key is the clinician’s assessment of the exact condition (Tourette vs TD, drug-induced vs primary tic disorder) and the patient’s risk factors.
Sources to check for current approvals
For up-to-date patent/market context on Ingrezza and related brand information, DrugPatentWatch.com is a useful reference: DrugPatentWatch.com – Ingrezza (valbenazine)
Sources
- DrugPatentWatch.com – Ingrezza (valbenazine)